Cell Growth & Differentiation, Vol 8, Issue 7 779-788, Copyright © 1997 by American Association of Cancer Research

ARTICLES

7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells

RT Bunch and A Eastman
Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.

A variety of agents, such as caffeine, have been shown to abrogate the DNA damage-dependent G2 checkpoint and enhance cytotoxicity. However, these agents are too toxic for clinical use. We have reported that the potent protein kinase inhibitor 7-hydroxystaurosporine (UCN-01) at nontoxic doses abrogates the G2 arrest caused by the DNA-damaging agent cisplatin. Here, using Chinese hamster ovary cells, we show that cisplatin causes predominantly an S-phase arrest; UCN-01 abrogates this S-phase arrest, causing progression of cells to G2 and, subsequently, apoptotic cell death. In searching for an explanation for this accelerate DNA synthesis, we discovered that UCN-01 caused translocation of proliferating cell nuclear antigen (PCNA) to the detergent-insoluble, DNA-bound fraction. PCNA acts as a sliding clamp for DNA polymerase delta. Sequestering of PCNA by p21waf1/cip1 is required for p53-dependent G1 arrest in damaged cells. However, the S-phase arrest occurs independently of p53 and p21waf1/cip1. Our results suggest that PCNA is also a component of this S-phase checkpoint, despite the fact that CHO cells are defective for p53, and no increase in p21waf1/cip1 was observed. The mechanism by which PCNA is sequestered in the absence of p21waf1/cip1 and the mechanism by which UCN-01 disrupts this sequestration remain to be elucidated.

This article has been cited by other articles:

				P. N. Lara Jr, P. C. Mack, T. Synold, P. Frankel, J. Longmate, P. H. Gumerlock, J. H. Doroshow, and D. R. Gandara The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial Clin. Cancer Res., June 15, 2005; 11(12): 4444 - 4450. [Abstract] [Full Text] [PDF]

				T. D. Bradshaw, C. S. Matthews, J. Cookson, E.-H. Chew, M. Shah, K. Bailey, A. Monks, E. Harris, A. D. Westwell, G. Wells, et al. Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols Cancer Res., May 1, 2005; 65(9): 3911 - 3919. [Abstract] [Full Text] [PDF]

				E. C. Dees, S. D. Baker, S. O'Reilly, M. A. Rudek, S. B. Davidson, C. Aylesworth, K. Elza-Brown, M. A. Carducci, and R. C. Donehower A Phase I and Pharmacokinetic Study of Short Infusions of UCN-01 in Patients with Refractory Solid Tumors Clin. Cancer Res., January 15, 2005; 11(2): 664 - 671. [Abstract] [Full Text] [PDF]

				H. Miao, J. A. Seiler, and W. C. Burhans Regulation of Cellular and SV40 Virus Origins of Replication by Chk1-dependent Intrinsic and UVC Radiation-induced Checkpoints J. Biol. Chem., January 31, 2003; 278(6): 4295 - 4304. [Abstract] [Full Text] [PDF]

				Q. Yu, J. La Rose, H. Zhang, H. Takemura, K. W. Kohn, and Y. Pommier UCN-01 Inhibits p53 Up-Regulation and Abrogates {gamma}-Radiation-induced G2-M Checkpoint Independently of p53 by Targeting Both of the Checkpoint Kinases, Chk2 and Chk1 Cancer Res., October 15, 2002; 62(20): 5743 - 5748. [Abstract] [Full Text] [PDF]

				A. M. Senderowicz The Cell Cycle as a Target for Cancer Therapy: Basic and Clinical Findings with the Small Molecule Inhibitors Flavopiridol and UCN-01 Oncologist, August 1, 2002; 7(90003): 12 - 19. [Abstract] [Full Text] [PDF]

				E. A. Kohn, N. D. Ruth, M. K. Brown, M. Livingstone, and A. Eastman Abrogation of the S Phase DNA Damage Checkpoint Results in S Phase Progression or Premature Mitosis Depending on the Concentration of 7-Hydroxystaurosporine and the Kinetics of Cdc25C Activation J. Biol. Chem., July 12, 2002; 277(29): 26553 - 26564. [Abstract] [Full Text] [PDF]

				T. Yamauchi, M. J. Keating, and W. Plunkett UCN-01 (7-Hydroxystaurosporine) Inhibits DNA Repair and Increases Cytotoxicity in Normal Lymphocytes and Chronic Lymphocytic Leukemia Lymphocytes Mol. Cancer Ther., February 1, 2002; 1(4): 287 - 294. [Abstract] [Full Text] [PDF]

				M. A. Shah and G. K. Schwartz Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181. [Abstract] [Full Text] [PDF]

				Z. Sever-Chroneos, S. P. Angus, A. F. Fribourg, H. Wan, I. Todorov, K. E. Knudsen, and E. S. Knudsen Retinoblastoma Tumor Suppressor Protein Signals through Inhibition of Cyclin-Dependent Kinase 2 Activity To Disrupt PCNA Function in S Phase Mol. Cell. Biol., June 15, 2001; 21(12): 4032 - 4045. [Abstract] [Full Text]

				G. W. Xu, C. L. Nutt, M. C. Zlatescu, M. Keeney, I. Chin-Yee, and J. G. Cairncross Inactivation of p53 Sensitizes U87MG Glioma Cells to 1,3-bis(2-Chloroethyl)-1-nitrosourea Cancer Res., May 1, 2001; 61(10): 4155 - 4159. [Abstract] [Full Text]

				Z. Shi, A. Azuma, D. Sampath, Y.-X. Li, P. Huang, and W. Plunkett S-Phase Arrest by Nucleoside Analogues and Abrogation of Survival without Cell Cycle Progression by 7-Hydroxystaurosporine Cancer Res., February 1, 2001; 61(3): 1065 - 1072. [Abstract] [Full Text]

				S. Harvey, R. Decker, Y. Dai, G. Schaefer, L. Tang, L. Kramer, P. Dent, and S. Grant Interactions between 2-Fluoroadenine 9-{beta}-D-Arabinofuranoside and the Kinase Inhibitor UCN-01 in Human Leukemia and Lymphoma Cells Clin. Cancer Res., February 1, 2001; 7(2): 320 - 330. [Abstract] [Full Text]

				W. Voigt, A. Bulankin, T. Müller, C. Schoeber, A. Grothey, C. Hoang-Vu, and H-J. Schmoll Schedule-dependent Antagonism of Gemcitabine and Cisplatin in Human Anaplastic Thyroid Cancer Cell Lines Clin. Cancer Res., May 1, 2000; 6(5): 2087 - 2093. [Abstract] [Full Text]

				A. M. Senderowicz and E. A. Sausville Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators J Natl Cancer Inst, March 1, 2000; 92(5): 376 - 387. [Abstract] [Full Text] [PDF]

				H. Jiang and L.-Y. Yang Cell Cycle Checkpoint Abrogator UCN-01 Inhibits DNA Repair: Association with Attenuation of the Interaction of XPA and ERCC1 Nucleotide Excision Repair Proteins Cancer Res., September 1, 1999; 59(18): 4529 - 4534. [Abstract] [Full Text] [PDF]

				B. Hu, X.-Y. Zhou, X. Wang, Z.-C. Zeng, G. Iliakis, and Y. Wang The Radioresistance to Killing of A1-5 Cells Derives from Activation of the Chk1 Pathway J. Biol. Chem., May 18, 2001; 276(21): 17693 - 17698. [Abstract] [Full Text] [PDF]